Pemgarda (pemivibart) is a monoclonal antibody that targets the SARS-CoV-2 spike protein. Clinicians are authorized to administer the drug, which must be infused for at least an hour and be followed by a repeat dose every three months. It is authorized for use in patients who are immunocompromised because of a medical condition, or those who are taking immunosuppressive medications and are unlikely to be protected with a COVID-19 vaccine.
In an ongoing phase 3 trial, the “calculated serum neutralizing antibody titers against JN.1” matched efficacy data for other monoclonal antibody products, the Massachusetts-based manufacturer, Invivyd, said in a news release.
Side effects include hypersensitivity, upper respiratory tract infection, viral infection, influenza-like illness, fatigue, headache and nausea; and its warning label lists anaphylaxis and cross-hypersensitivity with COVID-19 vaccines.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
